These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25355295)

  • 1. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.
    Graf von der Schulenburg JM; Frank M
    Eur J Health Econ; 2015 Mar; 16(2):113-8. PubMed ID: 25355295
    [No Abstract]   [Full Text] [Related]  

  • 2. Rare childhood diseases: how should we respond?
    Zurynski Y; Frith K; Leonard H; Elliott E
    Arch Dis Child; 2008 Dec; 93(12):1071-4. PubMed ID: 18684747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Public partners voices-why do communities support this dynamic?].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):61-2. PubMed ID: 24755182
    [No Abstract]   [Full Text] [Related]  

  • 4. Health systems sustainability for rare diseases. Preface.
    Ferrelli RM; Fantini B; Taruscio D
    Ann Ist Super Sanita; 2019; 55(3):249-250. PubMed ID: 31553318
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug patent plan gets mixed reviews.
    Butler D
    Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
    [No Abstract]   [Full Text] [Related]  

  • 6. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 8. [The challenges of medicoeconomic assessment, benefit for the patient].
    Meyer F
    Presse Med; 2012 May; 41 Suppl 1():S29-31. PubMed ID: 22503292
    [No Abstract]   [Full Text] [Related]  

  • 9. [Workshops A1 to A5].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):33-9. PubMed ID: 24755177
    [No Abstract]   [Full Text] [Related]  

  • 10. [Economic aspects of the strategy "Health for all in 2000"].
    Tsollner FK
    Sov Zdravookhr; 1989; (4):58-60. PubMed ID: 2727767
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 12. Social/economic costs and health-related quality of life in patients with rare diseases in Europe.
    López-Bastida J; Oliva-Moreno J; Linertová R; Serrano-Aguilar P
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():1-5. PubMed ID: 27023708
    [No Abstract]   [Full Text] [Related]  

  • 13. Austerity vs. growth--the impact of the current financial crisis on pharmaceutical innovation.
    Sharma D; Martini LG
    Int J Pharm; 2013 Feb; 443(1-2):242-4. PubMed ID: 23296153
    [No Abstract]   [Full Text] [Related]  

  • 14. Rare diseases mean big profits.
    Murphy RM
    Fortune; 2012 Sep; 166(4):24. PubMed ID: 23072062
    [No Abstract]   [Full Text] [Related]  

  • 15. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 16. [Round table 4. Speeding new therapeutic approaches for rare diseases: do we need new economical models or financial tools?].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):47-53. PubMed ID: 24755179
    [No Abstract]   [Full Text] [Related]  

  • 17. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 18. [Orphan diseases: what are the roles for associations? ].
    Araiedh J; Badoux T; Berweiler A; Egli L; Gartmann M
    Rev Med Suisse; 2013 Jul; 9(393):1435-6. PubMed ID: 23971330
    [No Abstract]   [Full Text] [Related]  

  • 19. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.